237 related articles for article (PubMed ID: 12241559)
1. The average cost of measles cases and adverse events following vaccination in industrialised countries.
Carabin H; Edmunds WJ; Kou U; van den Hof S; Nguyen VH
BMC Public Health; 2002 Sep; 2():22. PubMed ID: 12241559
[TBL] [Abstract][Full Text] [Related]
2. The cost of measles in industrialised countries.
Carabin H; Edmunds WJ; Gyldmark M; Beutels P; Lévy-Bruhl D; Salo H; Griffiths UK
Vaccine; 2003 Oct; 21(27-30):4167-77. PubMed ID: 14505896
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis of the 1996-1997 mass measles immunization campaigns in South Africa.
Uzicanin A; Zhou F; Eggers R; Webb E; Strebel P
Vaccine; 2004 Sep; 22(25-26):3419-26. PubMed ID: 15308367
[TBL] [Abstract][Full Text] [Related]
4. Future savings from measles eradication in industrialized countries.
Carabin H; Edmunds WJ
J Infect Dis; 2003 May; 187 Suppl 1():S29-35. PubMed ID: 12721889
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda.
Bishai D; Johns B; Nair D; Nabyonga-Orem J; Fiona-Makmot B; Simons E; Dabbagh A
J Infect Dis; 2011 Jul; 204 Suppl 1(Suppl 1):S107-15. PubMed ID: 21666151
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of an intervention project engaging Traditional and Religious Leaders to improve uptake of childhood immunization in southern Nigeria.
Oyo-Ita AE; Hanlon P; Nwankwo O; Bosch-Capblanch X; Arikpo D; Esu E; Auer C; Meremikwu M
PLoS One; 2021; 16(9):e0257277. PubMed ID: 34529714
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness, population-level effects, and heath economics of measles and rubella vaccination].
Wichmann O; Ultsch B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1260-9. PubMed ID: 23990088
[TBL] [Abstract][Full Text] [Related]
8. The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study.
Takahashi K; Ohkusa Y; Kim JY
BMC Health Serv Res; 2011 Oct; 11():254. PubMed ID: 21978107
[TBL] [Abstract][Full Text] [Related]
9. Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program.
Babigumira JB; Levin A; Burgess C; Garrison LP; Bauch CT; Braka F; Mbabazi WB; Nabyonga JO; Simons E; Dabbagh A
J Infect Dis; 2011 Jul; 204 Suppl 1():S116-23. PubMed ID: 21666152
[TBL] [Abstract][Full Text] [Related]
10. Measles control in developing and developed countries: the case for a two-dose policy.
Tulchinsky TH; Ginsberg GM; Abed Y; Angeles MT; Akukwe C; Bonn J
Bull World Health Organ; 1993; 71(1):93-103. PubMed ID: 8440043
[TBL] [Abstract][Full Text] [Related]
11. Cost-benefit analyses of supplementary measles immunisation in the highly immunized population of New Zealand.
Hayman DTS; Marshall JC; French NP; Carpenter TE; Roberts MG; Kiedrzynski T
Vaccine; 2017 Sep; 35(37):4913-4922. PubMed ID: 28802754
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of measles treatment: a systematic review.
Vo NX; Van Nguyen AT; Mai Tran HT; Thuy Truong LT; Bao Nguyen NN
J Pak Med Assoc; 2019 Jun; 69(Suppl 2)(6):S148-S154. PubMed ID: 31369545
[TBL] [Abstract][Full Text] [Related]
13. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
Peny JM; Gleizes O; Covilard JP
Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
[TBL] [Abstract][Full Text] [Related]
14. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
Thompson KM; Badizadegan ND
Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
[TBL] [Abstract][Full Text] [Related]
15. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis.
Zimmermann M; Frey K; Hagedorn B; Oteri AJ; Yahya A; Hamisu M; Mogekwu F; Shuaib F; McCarthy KA; Chabot-Couture G
Vaccine; 2019 Sep; 37(41):6039-6047. PubMed ID: 31471147
[TBL] [Abstract][Full Text] [Related]
16. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of three different vaccination strategies against measles in Zambian children.
Dayan GH; Cairns L; Sangrujee N; Mtonga A; Nguyen V; Strebel P
Vaccine; 2004 Jan; 22(3-4):475-84. PubMed ID: 14670330
[TBL] [Abstract][Full Text] [Related]
18. An economic evaluation of the current measles vaccination program: A case study in Zhejiang Province, east China.
Zeng Y; Luo M; Chen J; He H; Deng X; Xie S; Fang Y
Vaccine; 2019 May; 37(23):3071-3077. PubMed ID: 31040084
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of measles control during elimination in Ontario, Canada, 2015.
Ramsay LC; Crowcroft NS; Thomas S; Aruffo E; Teslya A; Heffernan JM; Gournis E; Hiebert J; Jaeger V; Jiaravuthisan M; Sharron J; Severini A; Deeks SL; Gubbay J; Mazzulli T; Sander B
Euro Surveill; 2019 Mar; 24(11):. PubMed ID: 30892178
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of second measles containing vaccine (MCV) dose: a systematic review of available evidence.
Bawa S; Wondimu A; Postma MJ; Hutubessy R; van Hulst M
Expert Rev Vaccines; 2024; 23(1):655-673. PubMed ID: 38924461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
